oncology

Johnson & Johnson Stock (JNJ) Today: FDA Fast‑Track Voucher Lifts Oncology Narrative as Talc Verdict Renews Legal Overhang

Johnson & Johnson stock (NYSE: JNJ) is starting the week at the center of two storylines that often tug the share price in opposite directions: accelerating momentum in oncology and a stubborn, headline‑driven litigation risk. On Monday, December 15, 2025,

15 December 2025

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Updated: Sunday, December 14, 2025 (U.S. markets last closed Friday, Dec. 12) Pfizer Inc. (NYSE: PFE) is ending the week in a familiar spot—trading in the mid‑$20s—while investors weigh a high dividend payout against a fast-moving set of catalysts: new

14 December 2025

Dividend News · Health Industry · Investment Analysis · NYSE:PFE · Pharmaceuticals · Stock Market

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing

13 December 2025

FDA Approval · Investment News · NYSE:JNJ · Oncology · Pharmaceuticals · Stock Market

Eli Lilly (LLY) After Hours: How a $6 Billion Bet, Fresh Oncology Data and Fed Rate Cut Set the Stage for December 11, 2025

Eli Lilly and Company (NYSE: LLY) closed just under the psychologically important $1,000 mark on Wednesday, December 10, 2025, then ticked slightly higher in after‑hours trading as investors digested a wave of company‑specific news against a backdrop of a fresh

11 December 2025

Federal Reserve · Investment Strategies · NYSE:LLY · Oncology · Pharma News · Stock Market

McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025

McKesson Corporation (NYSE: MCK) is ending 2025 as one of the standout performers in U.S. healthcare — but as of Wednesday, December 3, its stock is taking a breather. At the close, McKesson shares finished at $805.37, down 2.93% on

4 December 2025

Financial Outlook · Healthcare Industry · Investment Analysis · NYSE:MCK · Oncology · Stock Market

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its

2 December 2025

Business News · Healthcare Industry · Investing · NYSE:JNJ · Pharmaceuticals · Stock Market

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the

23 November 2025

Business News · Cancer Research · Dividends · Investing · Pharmaceuticals

GSK (GSK) news today — Nov 11, 2025: New AN2 TB collaboration, buyback activity filed, shares test 12‑month high

GSK Share Price Today, 20 November 2025: LON:GSK Edges Higher as Jefferies Lifts Target and Oncology Deal Builds Momentum

London, 20 November 2025 — GSK plc (LON:GSK, NYSE:GSK) finished Thursday’s session slightly higher, as upbeat broker commentary and a string of recent R&D announcements helped support the pharma giant’s share price against a volatile FTSE 100 backdrop. Key takeaways

20 November 2025

Analyst Ratings · Oncology · Pharma News · Share Prices · Stock Market

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on

17 November 2025

Biotech Industry · Mergers & Acquisitions · NASDAQ:CDTX · NYSE:JNJ · NYSE:MRK · NYSE:PFE · Oncology · Patent News · Pharmaceuticals

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs

11 November 2025

Business News · Mergers & Acquisitions · NYSE:MRK · NYSE:NVO · NYSE:PFE · Oncology · Pharmaceuticals · Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences (NASDAQ: COGT) announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor (GIST), sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival (mPFS)

10 November 2025

Biotechnology · Clinical Trials · NASDAQ:COGT · Oncology · Pharmaceutical News · Stock Market